Vedolizumab for Inflammatory Bowel Disease: Two-Year Results of the Initiative on Crohn and Colitis (ICC) Registry, A Nationwide Prospective Observational Cohort Study: ICC Registry - Vedolizumab

Vince B C Biemans, C Janneke van der Woude, Gerard Dijkstra, Andrea E van der Meulen-de Jong, Bas Oldenburg, Nanne K de Boer, Mark Löwenberg, Nidhi Srivastava, Alexander G L Bodelier, Rachel L West, Jeroen M Jansen, Annemarie C de Vries, Jeoffrey J L Haans, Dirk J de Jong, Marie J Pierik, Frank Hoentjen

Research output: Contribution to journalArticleAcademicpeer-review


Prospective data of vedolizumab treatment for patients with inflammatory bowel disease (IBD) beyond 1 year of treatment is scarce but needed for clinical decision making. We prospectively enrolled 310 patients with IBD (191 with Crohn's disease (CD) and 119 patients with ulcerative colitis (UC)) with a follow-up period of 104 weeks (interquartile range: 103-104) in a nationwide registry. The corticosteroid-free clinical remission rate (Harvey Bradshaw Index ≤ 4, Short Clinical Colitis Activity index ≤ 2) at weeks 52 and 104 were 28% and 19% for CD and 27% and 28% for UC, respectively. Fifty-nine percent maintained corticosteroid-free clinical remission between weeks 52 and 104. Vedolizumab with concomitant immunosuppression showed comparable effectiveness outcomes compared with vedolizumab monotherapy (week 104: 21% vs. 23%; P = 0.77), whereas 8 of 13 severe infections occurred in patients treated with concomitant immunosuppression. To conclude, the clinical effect was 19% for CD and 28% for UC after 2 years of follow-up regardless of concomitant immunosuppression.

Original languageEnglish
Pages (from-to)1189-1199
Number of pages11
JournalClinical Pharmacology and Therapeutics
Issue number5
Publication statusPublished - 1 May 2020

Cite this